BUZZ-Pennant Group jumps after Truist upgrades on growth outlook
Pennant Group's shares rose 3.22% after Truist Securities upgraded the stock to "buy" from "hold," citing strong operating trends and reduced reimbursement risk due to favorable 2026 Medicare rules. The brokerage raised the price target to $34, indicating a 19.7% upside. Pennant's acquisition integration is progressing well, with margins expected to normalize. All brokerages rate the stock as "strong buy" or "buy," with a median price target of $35.
Shares of home health care provider Pennant Group (PNTG.O) rise 3.22% in early trading session
Truist Securities upgrades PNTG to “buy” from “hold”, citing solid operating trends, strong sector demand and reduced reimbursement risk after a favorable 2026 home health rule
The 2026 Medicare payment rates and policies from U.S. regulators for home health providers is less restrictive than expected, easing concerns over Medicare reimbursement for home health providers, brokerage says
Brokerage also raised PT to $34 from $28, a 19.7% upside to stock’s last close
Truist analysts said the integration of Pennant’s $146.5 million acquisition of 54 Amedisys locations is progressing smoothly and margins are expected to normalize post-investment
6 of 6 brokerages rate the stock “strong buy” or “buy”; median PT is $35 — data compiled by LSEG
Including current session, PNTG up 10.54% YTD
